Trial of RAD in Triple Negative Metastatic Breast Cancer - Full Text View - - rad001 breast


rad001 breast

RAD was shown to have activity in human tumor cell lines originating from lung, breast, prostate, colon, kidney, melanoma and glioblastoma. RAD was.

Official Title: Phase II Trial of RAD Plus Carboplatin in Patients With Triple-​Negative Metastatic Breast Cancer. Study Start Date: June Actual Primary​.

The combination of gefitinib and RAD inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab.

Anticancer Res. Sep;31(9) The mTOR inhibitor RAD sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.

Afinitor (everolimus), formerly known as RAD, is a macrolide antibiotic used to treat pancreatic neuroendocrine tumours, gastric cancer and breast cancer.